RCRuihuan Chai

Ruihuan Chai

*This is an algorithmically generated author record based on publicly available information.

Ruihuan Chai has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Kai Zheng

    School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen 518055, China

    2 shared publications
  • Ling Ou

    School of pharmaceutical sciences (Shenzhen), Sun Yat-sen University, Shenzhen, China

    2 shared publications
  • Nan Li

    School of Pharmaceutical Sciences, Shenzhen University Medical School, Shenzhen, China

    2 shared publications
  • Shaoxiang Wang

    School of Pharmaceutical Sciences, Shenzhen University Medical School, Shenzhen 518000, China

    2 shared publications
  • Xiao Wang

    School of Pharmacy, Guangdong Medical University, Zhanjiang, PR China; Department of Pharmacy, State Key Laboratory of Neurology and Oncology Drug Development, Shenzhen People's Hospital (The First Affliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University), Shenzhen, 518020, PR China

    2 shared publications
  • Guifeng Xu

    Department of Pharmacy, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, P.R. China

    1 shared publication

Latest Publications

  • Open Access

    Circadian Clock Genes Act as Diagnostic and Prognostic Biomarkers of Glioma: Clinic Implications for Chronotherapy

    by Ruihuan Chai, Min Liao, Ling Ou, Qian Tang, Youfang Liang, Nan Li, Wei Huang, Xiao Wang, Kai Zheng, Shaoxiang Wang

    Gliomas are the most common primary intracranial tumors and closely related to circadian clock. Due to the high mortality and morbidity of gliomas, exploring novel diagnostic and early prognostic markers is necessary. Circadian clock genes (CCGs) play important roles in regulating the daily oscillation of biological processes and the development of tumor. Therefore, we explored the influences that the oscillations of circadian clock genes (CCGs) on diagnosis and prognosis of gliomas using bioinformatics. In this work, we systematically analyzed the rhythmic expression of CCGs in brain and found that some CCGs had strong rhythmic expression; the expression levels were significantly different between day and night. Four CCGs (ARNTL, NPAS2, CRY2, and DBP) with rhythmic expression were not only identified as differentially expressed genes but also had significant independent prognostic ability in the overall survival of glioma patients and were highly correlated with glioma prognosis in COX analysis. Besides, we found that CCG‐based predictive model demonstrated higher predictive accuracy than that of the traditional grade‐based model; this new prediction model can greatly improve the accuracy of glioma prognosis. Importantly, based on the four CCGs’ circadian oscillations, we revealed that patients sampled at night had higher predictive ability. This may help detect glioma as early as possible, leading to early cancer intervention. In addition, we explored the mechanism of CCGs affecting the prognosis of glioma. CCGs regulated the cell cycle, DNA damage, Wnt, mTOR, and MAPK signaling pathways. In addition, it also affects prognosis through gene coexpression and immune infiltration. Importantly, ARNTL can rhythmically modulated the cellular sensitivity to clinic drugs, temozolomide. The optimal point of temozolomide administration should be when ARNTL expression is highest, that is, the effect is better at night. In summary, our study provided a basis for optimizing clinical dosing regimens and chronotherapy for glioma. The four key CCGs can serve as potential diagnostic and prognostic biomarkers for glioma patients, and ARNTL also has obvious advantages in the direction of glioma chronotherapy.


  • Open Access

    Upregulation of Centromere Proteins as Potential Biomarkers for Esophageal Squamous Cell Carcinoma Diagnosis and Prognosis

    by Xiao Wang, Minshan Lai, Yue Wang, Ruihuan Chai, Nan Li, Ling Ou, Kai Zheng, Jieling Li, Guifeng Xu, Shaoqi Wang, et al.

    Esophageal squamous cell carcinoma (ESCC) has a high incidence and low survival rate, necessitating the identification of novel specific biomarkers. Centromere-associated proteins (CENPs) have been reported to be biomarkers for many cancers, but their roles in ESCC have seldom been investigated. Here, the potential clinical roles of CENPs in ESCC patients were demonstrated by a systematic bioinformatics analysis. Most CENP-encoding genes were differentially expressed between tumor and normal tissues. CENPA, CENPE, CENPF, CENPI, CENPM, CENPN, CENPQ, and CENPR were upregulated universally in the three datasets. Survival analysis demonstrated that high expression of CENPE and CENPQ was positively correlated with the outcomes of ESCC patients. The CENPE-based forecast model was more accurate than the tumor-node-metastasis (TNM) staging-based model, which was classified as stage I/II vs. III/IV. More importantly, the forecast model based on the commonly upregulated CENPs exhibited a much higher area under the curve (AUC) value (0.855) than the currently known TTL, ZNF750, AC016205.1, and BOLA3 biomarkers. The nomogram model integrating the CENPs, TNM stage, and sex was highly accurate in the prognosis of ESCC patients ( ). Besides, gene set enrichment analysis (GSEA) demonstrated that CENPE expression is significantly correlated with cell cycle, G2/M checkpoint, mitotic spindle, p53, etc. Finally, in validation experiments, we also found that CENPE and CENPQ were significantly overexpressed in esophageal cancer cells. Taken together, these results clearly suggest that CENPs are clinically promising diagnostic and prognostic biomarkers for ESCC patients.